Chronic Urticaria: all 194 studies

Page 2 of 2. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous UrticariaTerminatedNCT07316114
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic EnzymesCompletedNCT07230418Phase 1
• A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in GermanyActive, not recruitingNCT06991608
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Active, not recruitingNCT06931405Phase 2
• Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)CompletedNCT06873516Phase 2
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingNCT06868212Phase 3
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous UrticariaWithdrawnNCT06795373Phase 2
• A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsTerminatedNCT06736262Phase 2
• A Study of Single Dose of LP-003 in Healthy Adult SubjectsActive, not recruitingNCT06604949Phase 1
• Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001CompletedNCT06577116Phase 1
• Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis SuppurativaTerminatedNCT06555328Phase 2
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingNCT06455202Phase 3
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingNCT06445023Phase 3
• A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsActive, not recruitingNCT06396026Phase 3
• To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaCompletedNCT06365879Phase 3
• A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- AntihistaminesTerminatedNCT06353971Phase 1/2
• A Study of Single and Multiple Doses of LP-003 in Healthy Adult ParticipantsCompletedNCT06294288Phase 1
• Antiplatelet Therapy in Chronic UrticariaActive, not recruitingNCT06268470Phase 2
• Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT06228560Phase 2
• Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)CompletedNCT06162728Phase 1/2
• Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)SuspendedNCT06108869Not applicable
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous UrticariaCompletedNCT06072157Phase 1
• Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in ChildrenCompletedNCT06063044
• A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in ChinaCompletedNCT06053801
• Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingNCT06042478Phase 3
• A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic DiseasesCompletedNCT05960708Phase 1
• Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedNCT05774639Phase 3
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive, not recruitingNCT05677451Phase 3
• Positive Psychotherapy-Based Counseling (PPT)Status unknownNCT05513079Not applicable
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibActive, not recruitingNCT05513001Phase 3
• Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%CompletedNCT05461456Phase 1
• Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.CompletedNCT05373355Phase 1
• A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT05368285Phase 2
• A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous UrticariaCompletedNCT05335499Phase 2
• A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous UrticariaStatus unknownNCT05298215Phase 2
• STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and AngioedemaStatus unknownNCT05169645
• A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous UrticariaWithdrawnNCT05129423Phase 2
• Modified Xiao-Feng Powder for Chronic UrticariaCompletedNCT04967092Phase 2
• Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous UrticariaStatus unknownNCT04944602Phase 3
• Global Managed Access Program Cohort for Ligelizumab in CSUNo longer availableNCT04903613
• Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous UrticariaStatus unknownNCT04893980Phase 2/3
• Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaWithdrawnNCT04827589Phase 2
• Molecular Endotypes of Chronic Idiopathic UrticariaActive, not recruitingNCT04774315Phase 4
• Real Life Use of Omalizumab in Chronic UrticariaStatus unknownNCT04584190
• Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous UrticariaCompletedNCT04583475
• A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT04538794Phase 1
• Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic UrticariaTerminatedNCT04513548Phase 1
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria ParticipantsTerminatedNCT04444466Phase 1
• Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT04439955Phase 2
• Frequency of Parasite Infestation in Patients With Chronic Spontaneous UrticariaCompletedNCT04314999
• Shotblocker® Use in Subcutaneous InjectionCompletedNCT04210323Not applicable
• Tranexamic Acid and Spontaneous Chronic UrticariaStatus unknownNCT03789422Phase 4
• Dupilumab in Chronic Spontaneous UrticariaCompletedNCT03749135Phase 2
• A Longitudinal Observational Study of Patients Undergoing Therapy for IMISCActive, not recruitingNCT03661866
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU PatientsCompletedNCT03632291Phase 1
• Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.Status unknownNCT03443362
• Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.CompletedNCT03296358Not applicable
• Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor AntagonistCompletedNCT03293225
• Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal AntibodyCompletedNCT03183024Phase 4
• Quality of Life in Patients With Chronic UrticariaStatus unknownNCT03163875
• Detection of Viral Particels in Urticaria PatientsCompletedNCT03151902
• Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune UrticariaCompletedNCT02824393Early Phase 1
• Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic UrticariaCompletedNCT02814630Not applicable
• A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)CompletedNCT02626221
• AWARE - Chronic UrticariaCompletedNCT02435238
• Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous UrticariaCompletedNCT02372604Phase 3
• Chronic Urticaria - Long Term Assessment of Effects of RupatadineTerminatedNCT02358265Phase 3
• Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control TestCompletedNCT02285049
• Bilastine Updosing in Chronic Spontaneous UrticariaCompletedNCT02213367Phase 3
• Efficacy and Safety of Omalizumab in Chronic Idiopathic UrticariaStatus unknownNCT02166151Phase 3
• Dietary Treatment for Chronic UrticariaTerminatedNCT02047136Not applicable
• Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in ThailandCompletedNCT02000648
• Methotrexate in the Treatment of Chronic Idiopathic UrticariaCompletedNCT01960283Phase 3
• Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria PatientsCompletedNCT01803763Phase 2/3
• Study of the Effects of Chinese Herbal Medicine on Chronic UrticariaCompletedNCT01715740Phase 3
• Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic UrticariaCompletedNCT01713725Phase 2
• Profiling Urticaria for the Identification of SubtypesCompletedNCT01637116
• Efficacy Study of Canakinumab to Treat UrticariaStatus unknownNCT01635127Phase 2
• Validation of an Urticaria Control TestCompletedNCT01614834
• Development of an Urticaria Control TestCompletedNCT01610128
• T Cell Function in Chronic Idiopathic UrticariaStatus unknownNCT01425593
• Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High DosesCompletedNCT01250652Phase 4
• Stress Intervention for Chronic UrticariaCompletedNCT01111136Not applicable
• Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)CompletedNCT01081574Phase 1/2
• Hydroxychloroquine Efficacy in Chronic UrticariaWithdrawnNCT01073852Not applicable
• Response of Urticaria to Stress InterventionWithdrawnNCT01047137Not applicable
• Etanercept for the Treatment of Chronic UrticariaWithdrawnNCT01030120Phase 2/3
• The Effect of Levocetirizine on Inflammatory Mediators in DermatographismTerminatedNCT01008592
• A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)CompletedNCT00783354Phase 4
• Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)CompletedNCT00757562Phase 3
• Association of Thyroid Autoimmunity and Chronic UrticariaCompletedNCT00737451
• Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)CompletedNCT00598611Phase 3
• The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic UrticariaStatus unknownNCT00346606Phase 4
• A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic UrticariaTerminatedNCT00189878Phase 2

← Chronic Urticaria overview